Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $26.00. The company’s shares opened today at $10.93.
Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and BioLife Solutions. According to TipRanks, Byrnes has an average return of -11.9% and a 32.30% success rate on recommended stocks.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $22.40, implying a 104.94% upside from current levels. In a report released today, Craig-Hallum also maintained a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on BioLife Solutions’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $39.51 million and a GAAP net loss of $10.2 million. In comparison, last year the company earned a revenue of $40.53 million and had a GAAP net loss of $72.88 million
Based on the recent corporate insider activity of 176 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
- BioLife Solutions Reports Third Quarter 2023 Financial Results
- BLFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insider Trading: BioLife Solutions Stock (NASDAQ:BLFS) Gains on Huge Insider Buy
- BioLife Solutions price target lowered to $20 from $25 at TD Cowen
- BioLife Solutions reports Q3 preliminary revenue $33.3 M, consensus $32.72M
